Cargando…

Weight Gain during Neoadjuvant Chemotherapy is Associated with Worse Outcome among the Patients with Operable Breast Cancer

PURPOSE: This study was aimed at identifying the influence of initial weight and weight change during neoadjuvant chemotherapy (NAC) on pathologic complete response (pCR) and long-term survival in Chinese patients with operable breast cancer. METHODS: We conducted a retrospective study using data fr...

Descripción completa

Detalles Bibliográficos
Autores principales:	Fang, Qiong, Huang, Jiahui, Gan, Lu, Shen, Kunwei, Chen, Xiaosong, Wu, Beiwen
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Korean Breast Cancer Society 2019
Materias:	Original Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6769390/ https://www.ncbi.nlm.nih.gov/pubmed/31598340 http://dx.doi.org/10.4048/jbc.2019.22.e37

Ejemplares similares

Prolonged Time to Adjuvant Chemotherapy Initiation Was Associated with Worse Disease Outcome in Triple Negative Breast Cancer Patients
por: Cai, Lifen, et al.
Publicado: (2020)

Ki67 increase after core needle biopsy associated with worse disease outcome in HER2-negative breast cancer patients
por: Tong, Yiwei, et al.
Publicado: (2023)

Sonography with vertical orientation feature predicts worse disease outcome in triple negative breast cancer
por: Wang, Haoyu, et al.
Publicado: (2019)

Accuracy of ultrasonographic changes during neoadjuvant chemotherapy to predict axillary lymph node response in clinical node-positive breast cancer patients
por: Li, Zhuoxuan, et al.
Publicado: (2022)

Association of tumor‐infiltrating lymphocytes before and after neoadjuvant chemotherapy with pathological complete response and prognosis in patients with breast cancer
por: Hong, Jin, et al.
Publicado: (2021)

Non-anthracycline-containing docetaxel and cyclophosphamide regimen is associated with sustained worse outcome compared with docetaxel, anthracycline and cyclophosphamide in neoadjuvant treatment of triple negative and HER2-positive breast cancer patients: updated follow-up data from NATT study
por: Chen, Xiaosong, et al.
Publicado: (2016)

The Value of Tumor Infiltrating Lymphocytes (TILs) for Predicting Response to Neoadjuvant Chemotherapy in Breast Cancer: A Systematic Review and Meta-Analysis
por: Mao, Yan, et al.
Publicado: (2014)

Nanoparticle albumin-bound paclitaxel as neoadjuvant chemotherapy of breast cancer: a systematic review and meta-analysis
por: Zong, Yu, et al.
Publicado: (2017)

Association between tumor molecular subtype, clinical stage and axillary pathological response in breast cancer patients undergoing complete pathological remission after neoadjuvant chemotherapy: potential implications for de-escalation of axillary surgery
por: Hong, Jin, et al.
Publicado: (2021)

Time interval between breast cancer diagnosis and surgery is associated with disease outcome
por: Zhu, Siji, et al.
Publicado: (2023)

Pathological complete response, category change, and prognostic significance of HER2-low breast cancer receiving neoadjuvant treatment: a multicenter analysis of 2489 cases
por: Zhu, Siji, et al.
Publicado: (2023)

A Long Noncoding RNA Signature That Predicts Pathological Complete Remission Rate Sensitively in Neoadjuvant Treatment of Breast Cancer()
por: Wang, Gen, et al.
Publicado: (2017)

Compliance with multidisciplinary team recommendations and disease outcomes in early breast cancer patients: An analysis of 4501 consecutive patients
por: Yang, Xingxia, et al.
Publicado: (2020)

Prognostic Factors and Surgery for Breast Cancer Patients With Locoregional Recurrence: An Analysis of 5,202 Consecutive Patients
por: Huang, Jiahui, et al.
Publicado: (2021)

Obesity or Overweight Is Associated with Worse Pathological Response to Neoadjuvant Chemotherapy among Chinese Women with Breast Cancer
por: Chen, Sheng, et al.
Publicado: (2012)

High expression of MORC2 predicts worse neoadjuvant chemotherapy efficacy in triple negative breast cancer
por: Liao, Xiaohong, et al.
Publicado: (2023)

Association of Biomarker Discrepancy and Treatment Decision, Disease Outcome in Recurrent/Metastatic Breast Cancer Patients
por: Lu, Yujie, et al.
Publicado: (2021)

Weight change during chemotherapy changes the prognosis in non metastatic breast cancer for the worse
por: Thivat, Emilie, et al.
Publicado: (2010)

Association of serum lipid levels and clinical outcomes in early breast cancer patients
por: Dong, Shuwen, et al.
Publicado: (2023)

Decision-making of Adjuvant Chemotherapy for Breast Cancer Patients with Discordant Risk Classifications between Clinical-Pathological Factors and 21-gene Recurrence Score
por: Gao, Weiqi, et al.
Publicado: (2020)

Association of molecular subtype concordance and survival outcome in synchronous and metachronous bilateral breast cancer
por: Ding, Shuning, et al.
Publicado: (2021)

Long Noncoding RNA Signature and Disease Outcome in Estrogen Receptor-Positive Breast Cancer Patients Treated with Tamoxifen
por: Wang, Gen, et al.
Publicado: (2018)

Clinicopathological characteristics, adjuvant chemotherapy decision and disease outcome in patients with breast cancer with a 21-gene recurrence score of 26–30
por: Yu, Jing, et al.
Publicado: (2020)

Neoadjuvant chemotherapy and trastuzumab versus neoadjuvant chemotherapy followed by post-operative trastuzumab for patients with HER2-positive breast cancer
por: Palmieri, Carlo, et al.
Publicado: (2015)

Does neoadjuvant chemotherapy increase breast conservation in operable breast cancer: an Egyptian experience
por: Abdel-Bary, N, et al.
Publicado: (2009)

The Relevance of Breast Cancer Subtypes in the Outcome of Neoadjuvant Chemotherapy
por: Straver, M. E., et al.
Publicado: (2010)

Retrospective analysis of 119 Chinese noninflammatory locally advanced breast cancer cases treated with intravenous combination of vinorelbine and epirubicin as a neoadjuvant chemotherapy: a median follow-up of 63.4 months
por: Huang, Ou, et al.
Publicado: (2009)

Diverse Distribution and Gene Expression on the 21-Gene Recurrence Assay in Breast Cancer Patients with Locoregional Recurrence Versus Distant Metastasis
por: Lu, Yujie, et al.
Publicado: (2021)

Inhibition of histone deacetylases attenuates tumor progression and improves immunotherapy in breast cancer
por: Lian, Bi, et al.
Publicado: (2023)

Association between weight gain during adjuvant chemotherapy for early‐stage breast cancer and survival outcomes
por: Schvartsman, Gustavo, et al.
Publicado: (2017)

Association of sonographic features and molecular subtypes in predicting breast cancer disease outcomes
por: Wang, Haoyu, et al.
Publicado: (2020)

Do patients with weight loss have a worse outcome when undergoing chemotherapy for lung cancers?
por: Ross, P J, et al.
Publicado: (2004)

Tumor size is associated with adjuvant chemotherapy benefit in T1N0M0 triple-negative breast cancer: a multicenter and propensity score matched analysis
por: Wu, Chenghui, et al.
Publicado: (2023)

A large-cohort retrospective study of metastatic patterns and prognostic outcomes between inflammatory and non-inflammatory breast cancer
por: Wang, Zheng, et al.
Publicado: (2020)

Single‐cell RNA sequencing in breast cancer: Understanding tumor heterogeneity and paving roads to individualized therapy
por: Ding, Shuning, et al.
Publicado: (2020)

Pre-operative thrombotic complications of neoadjuvant chemotherapy for breast cancer: Implications for immediate breast reconstruction
por: Richards, K., et al.
Publicado: (2014)

21-Gene Recurrence Score and Adjuvant Chemotherapy Decision for Breast Cancer Patients with Positive Lymph Nodes
por: Tong, Yiwei, et al.
Publicado: (2019)

Association of Ki-67 Change Pattern After Core Needle Biopsy and Prognosis in HR+/HER2− Early Breast Cancer Patients
por: Li, Shuai, et al.
Publicado: (2022)

Outcome after neoadjuvant chemotherapy in Asian breast cancer patients
por: Lim, Li Yan, et al.
Publicado: (2016)

Molecular Subtype May Be More Associated With Prognosis and Chemotherapy Benefit Than Tumor Size in T1N0 Breast Cancer Patients: An Analysis of 2,168 Patients for Possible De-Escalation Treatment
por: Zhu, Siji, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_j8e2f3n7iod10k5tm3kuhhhb0o